Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model

BACKGROUND: Aripiprazole lauroxil (AL) is a long-acting injectable medication approved for the treatment of schizophrenia. Current AL regimens are 441 mg, 662 mg, and 882 mg administered monthly (every 4 weeks [q4wk]), or 882 mg administered every 6 weeks (q6wk). OBJECTIVE: We examined the feasibili...

Descripción completa

Detalles Bibliográficos
Autores principales: Hard, Marjie L., Mills, Richard J., Sadler, Brian M., Wehr, Angela Y., Weiden, Peter J., von Moltke, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511303/
https://www.ncbi.nlm.nih.gov/pubmed/28597226
http://dx.doi.org/10.1007/s40263-017-0447-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511303/
https://www.ncbi.nlm.nih.gov/pubmed/28597226
http://dx.doi.org/10.1007/s40263-017-0447-7

Ejemplares similares